Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
+1.19 (0.89%)
Apr 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 130.57 - 135.52
52 week 71.99 - 153.10
Open 133.13
Vol / Avg. 3.11M/2.96M
Mkt cap 44.82B
P/E     -
Div/yield     -
EPS -2.60
Shares 333.41M
Beta 0.81
Inst. own 86%
May 5, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Release (Estimated) Add to calendar
Feb 27, 2014
Q4 2013 Valeant Pharmaceuticals International, Inc. Earnings Release
Feb 27, 2014
Q4 2013 Valeant Pharmaceuticals International, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 6.06% -14.97%
Operating margin 9.11% -8.22%
EBITD margin - 39.96%
Return on average assets 1.78% -3.76%
Return on average equity 9.86% -19.60%
Employees 17,200 -
CDP Score - -


+1-514-7446792 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On December 12, 2011, it acquired assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. (Janssen). In August 2013, Valeant Pharmaceuticals International Inc completed the acquisition of Bausch + Lomb Holdings Incorporated. In January 2014, the Company's wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.